Considerations on discontinuing natalizumab for the treatment of multiple sclerosis

Joseph R. Berger, Diego Centonze, Giancarlo Comi, Christian Confavreux, Gary Cutter, Gavin Giovannoni, Ralf Gold, Hans Peter Hartung, Fred Lublin, Augusto Miravalle, Xavier Montalban, Paul O'Connor, Tomas Olsson, Chris H. Polman, Olaf Stuve, Jerry S. Wolinsky, Tjalf Ziemssen

Research output: Contribution to journalLetter

34 Scopus citations
Original languageEnglish (US)
Pages (from-to)409-411
Number of pages3
JournalAnnals of Neurology
Volume68
Issue number3
DOIs
StatePublished - Sep 2010

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Berger, J. R., Centonze, D., Comi, G., Confavreux, C., Cutter, G., Giovannoni, G., Gold, R., Hartung, H. P., Lublin, F., Miravalle, A., Montalban, X., O'Connor, P., Olsson, T., Polman, C. H., Stuve, O., Wolinsky, J. S., & Ziemssen, T. (2010). Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Annals of Neurology, 68(3), 409-411. https://doi.org/10.1002/ana.22083